COSCIENS Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of ET8?
Owner TypeNumber of SharesOwnership Percentage
Private Companies5,9000.16%
Institutions17,5850.476%
Individual Insiders41,3941.12%
Hedge Funds221,5705.99%
General Public3,410,45592.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 204.5%.


Top Shareholders

Top 16 shareholders own 7.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.99%
GoodWood Inc.
221,570€651.3k24%16.99%
0.98%
Gilles Gagnon
36,062€106.0k0%no data
0.16%
Prodev Pharma Inc
5,900€17.3k0%no data
0.16%
National Bank Investments Inc.
5,796€17.0k587%no data
0.12%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
4,536€13.3k-8.12%no data
0.1%
Toronto-Dominion Bank, Banking Investments
3,717€10.9k0%no data
0.068%
RBC Dominion Securities Inc., Asset Management Arm
2,527€7.4k-3.37%no data
0.065%
William Li
2,397€7.0k0%no data
0.05%
Ulrich Kosciessa
1,848€5.4k0%no data
0.024%
Geode Capital Management, LLC
897€2.6k-4.47%no data
0.021%
Stacy Prefontaine
767€2.3k0%no data
0.0087%
Dennis Turpin
320€941.10%no data
0.0014%
Osaic Wealth, Inc. , Asset Management Arm
50€146.70%no data
0.001%
Tower Research Capital Europe Limited
38€111.98.57%no data
0.0006%
Truvestments Asset Management LLC
22€65.20%no data
0.00005%
Planning Capital Management Corp.
2€5.40%no data